Cancer Research, Awards and Achievements

Awards and Achievements

BioMark Diagnostics Inc. is highly accomplished and recognized for its cancer research and cancer detection technology development.

Collaborations

Cancer Research Awards, Grants and Recognitions

BioMark has received funding from many government agencies including:

NRC IRAP
NRC Engage
Genome BC
Government of Manitoba
DFAIT Canada.

Biomark maintains collaborative studies with:

University of British Columbia
University of Manitoba
University of Victoria
University of Waterloo
University of Alberta

To expand our metabolomics studies, Biomark has engaged Bio banks across Canada and United States.

Government

Funding and Grants for Cancer Research

Collaborative Health Research Projects (CHRP) funding in 2019 – The application was Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) and in collaboration with the Social Sciences and Humanities Research Council (SSHRC). BioMark is the industrial partner on the grant .
Going Global Innovation (GGI) – The Canadian Trade Commissioner Service – Offered funding to support BioMark to Japan and United States seeking partners for the purpose of establishing a collaborative R&D agreement in 2018
NSERC Engage Grants – 6 grants with professors from University of British Columbia, University of Victoria, University of Waterloo, University of Alberta and with University of Manitoba.
Mitacs – 5 projects have been supported by Mitacs program. Have commitment to fund additional post doctoral students for BioMark in coming year.
CSB – Commercialization Support for Business under Minister of Jobs and the Economy, Government of Manitoba
BIAP – Business Innovation Access Program under NRC-IRAP – Novel Recombinant Antibodies to Assess SSAT-1 Activity as a Biomarker for the Diagnosis of Cancer lead by Dr. Horacio Bach
NRC – IRAP Funding for 2013 – developing prototypes for cancer screening kits and IR system
Genome BC – Founding for Raman Quantification of Cancer Biomarkers for Early Lung Cancer Detection with Dr. Reuven Gordon and Dr. Fraser Hof from University of Victoria, British Columbia

Foundations

Maunders McNeil Foundation provided financial support for clinical studies and publications in scientific peer reviewed papers by Dr. Andrew Maksymiuk and other researchers and investigators affiliated with BioMark Diagnostics Inc.

Achievements

Achievements, Awards and Recognitions for Cancer Research and Early Stage Cancer Detection Technology

BioMark contributed two scientific publications in 2018
Successfully obtained three major ethics approval and commissioning of trials in 2018
BioMark has been short listed for CHRP’s application submitted by Drs. Don Miller, Thomas Klonish, Ted Lakowski, Marshall Pitz and Dr. David Wishart for a focused study to investigate SAT1 as a biomarker target for improved detection and clinical management of brain tumors.
BioMark expanded its scientific, clinical and data science capabilities by recruiting leading experts into its advisory team.
BioMark was granted several patents in Europe and China in 2018. BioMark continues to file trademark and patents in specific jurisdictions for all its patents.
New patents were filed as new panels of biomarkers were discovered. These patents will be critical as we stake our claims in the oncology diagnostic arena.
BioMark partnered with Alberta Machine Intelligence Institute to incorporate machine learning and generate artificial intelligence on its lung cancer retrospective studies. The goal was to improve assay performance by incorporating additional data.
Currently in development mode for a cost-effective mass spec system for quantification and qualification of markers with goal to further reduce cost per test
BioMark has signed several Non-Disclosure Agreements with distinguished lab / diagnostics / data analytic companies
BioMark and TMIC were part of the finalist in Genome Canada’s LSARP competition in 2018.
Going Global Award to meet with 3 major Japanese companies – Awarded by Global Affairs Canada – 2017
BioMark was invited and selected to present at various global Oncology and biomarker conferences and symposiums – London, Paris, Beijing and Boston.
Canadian Technology Accelerator Program – BioMark and the other 4 companies were selected as the first group of Canadian companies to go to Mission Bay in Silicon Valley
Regional Awards for New Technology – a prestigious award, supported by the National Research Council of Canada – BioMark Finalist
BioMark was selected for AdvaMed 2011 and 2013 in Washington DC funded by DFAIT